Keywords
Aurolab aqueous drainage implant, glaucoma surgery, refractory glaucoma, trabeculectomy, intraocular pressure.
This article is included in the Datta Meghe Institute of Higher Education and Research collection.
Aurolab aqueous drainage implant, glaucoma surgery, refractory glaucoma, trabeculectomy, intraocular pressure.
High intraocular pressure (IOP), optic nerve deterioration, and visual impairments are the hallmarks of glaucoma, a condition that is a primary cause of blindness.1 Glaucoma is a multifactorial optic neuropathy that manifests as classical optic nerve head characteristics and corresponding modifications in the visual field and accelerated ganglion cell ageing in the retina that in the presence or absence of any angle abnormalities, may or may not be connected to underlying disease cause.2 Neovascular glaucoma, the secondary glaucoma brought on by uveitis, and angle recession are a few kinds of glaucoma that typically have poor responses to standard medical treatments and surgical methods.3,4 Intraocular pressure (IOP) is the main focus of currently available standard treatments because it has been demonstrated that increased IOP causes the death of brain cells in glaucoma patients.5 Additionally, IOP is now thought to be the only risk factor for glaucoma that is practically adjustable and has benefits for maintaining the visual field (VF).
Uveitis is an inflammation and swelling of uvea, the central layer of the eye. In Europe and the United States, it causes 5% to 20% of blindness cases.6 Because it could be challenging to achieve a suitable IOP with medical interventions and procedures, uveitic glaucoma is challenging to control. Uveitic glaucoma is treated using a variety of methods. Trabeculectomy is one of the most frequently performed surgeries. The primary difficulty with this is fibrosis of bleb.7,8 Although anti-fibrotic medications like mitomycin C have been applied during surgery, but the filtering surgery’s rate of success is still questionable.9
Compared to other refractory glaucoma, filtration surgery for uveitic glaucoma has lesser success rates due to the repeated inflammatory response of uveitis that occurs among patients.10 Aqueous drainage devices have become popular in recent years as glaucoma treatments. A preference for tube shunts that is increasing and trabeculectomy that is losing favour is also seen in surveys conducted by the American Glaucoma Society.11
The increased usage of tube shunt surgery as a substitute to trabeculectomy is likely a result of concern over bleb-related problems like bleb leaks and bleb infections. The tube shunts when first developed, were often only used for glaucomas that had not responded to filtering surgery and were refractory. However, implantation of these devices in glaucomas with improved surgical prognosis has been motivated by a rising body of favourable experience with them. Refractory glaucoma is defined as uncontrolled intraocular pressure with evidence of deterioration in the optic nerve or visual field despite maximally tolerable anti-glaucoma medications (topical and/or systemic), previously unsuccessful non-seton surgical treatment, a combination of surgery and medications, or a high risk of failure for trabeculectomy.12
With untreated primary and refractory glaucomas, the current study compares the clinical outcomes of glaucoma drainage devices and traditional trabeculectomy in patients.
1) To assess the clinical results of traditional trabeculectomy in glaucoma patients with uncontrolled primary glaucoma.
2) To assess the clinical results of traditional trabeculectomy in glaucoma patients who have refractory glaucoma.
3) To evaluate the clinical results of drainage devices in patients with uncontrolled primary glaucoma.
4) To evaluate the effectiveness of glaucoma drainage devices in people with refractory glaucoma.
5) To compare the treatment results of traditional trabeculectomy with glaucoma drainage devices in patients with uncontrolled primary glaucoma.
6) To compare the therapeutic results of traditional trabeculectomy and glaucoma drainage devices in glaucoma patients who have not responded to other treatments.
Trial design - Single Centric, hospital based cross sectional study.
This is a hospital-based study in which subjects would be recruited from the OPD of ophthalmology at Acharya Vinobha Bhave Rural Hospital Sawangi, Meghe, Wardha, Maharashtra, with clearance from the institutional ethical committee of Datta Meghe institute of higher education and research and will adhere to the principles of the Helsinki Declaration. The specifics of the surgery will be properly explained to each patient. The study will gradually recruit the patients who meet the inclusion criteria. This study will be carried out under standard preoperative, intraoperative and post operative conditions by a single experienced surgeon. Study participants will be divided into two groups. Group-A (Trabeculectomy group) and Group-B (Glaucoma Drainage Device group) taking into consideration factors such as staphyloma, scleral thinning and high myopia, participants with this pathology will be undergoing glaucoma drainage device implantation. Subjects will be invited & screened for inclusion and exclusion criteria for selection. All patients in both groups will be followed up on a monthly basis for the next two years. At each follow-up, we evaluate IOP, visual acuity and need of anti-glaucoma medications in post-operative patients, and both groups are compared.
There will be a clinical history gathered and best corrected visual acuity (Snellen’s chart), slit lamp examination, Intra Ocular Pressure measurement (applanation tonometer), fundoscopy (slit lamp biomicroscopy with 90 D, direct, and indirect ophthalmoscopy with 20 D) and gonioscopy are all included in a thorough ophthalmic checkup. OCT-RNFL and Perimetry will be done. Patients who underwent trabeculectomy and glaucoma drainage device surgery (Aurolab aqueous drainage implant) will be included in the study.
A conjunctival flap precisely fornix based will be made, and the corneal traction suture will be positioned at the 12 o’clock position. Gentle diathermy will be used to cauterise the blood vessels. A rectangular scleral flap of 4×3 mm with partial thickness will be made and a trab of 0.8×2.0 mm will be achieved followed by a Peripheral Iridectomy. A single 10-0 nylon suture will be given to secure the scleral flap, with possible extra sutures in between the sutures and at the flap’s corners. The conjunctiva at the limbus will be stitched up with a 10-0 nylon suture.
Tenon’s tissue will be dissected after a conjunctival flap (fornix based). The operating surgeon will choose the implant insertion site depending on the amount of conjunctival scarring, if any, and whether it will be supero-temporal or infero-nasal. Using muscle hooks, adjoining recti muscles in the desired quadrant will be isolated. After that, the AADI implant will be prepped to look for possible manufacturing flaws. The end plate will then be positioned so that the front edge of the plate will be roughly 8 mm away from the limbus, in between the neighbouring recti muscles. After that, 9-0 Nylon sutures will be used to secure the plate to the underlying sclera by passing them through the implant’s fixation holes. The tube’s connection to the sclera will be stabilised using a non-compressing mattress suture. By tying it with a 6-0 vicryl suture, temporary tube occlusion will be accomplished. A 23-gauge needle will be used to produce a scleral fistula at a distance of roughly 3 mm from the limbus. In order for the tube to lie 1-2 mm past the surgical limbus, it will then be anteriorly bevelled up and introduced into the AC through the scleral tract. The operating surgeon will directly observe the tube to ensure its place. Fenestrations in the tube will be constructed, necessitating short-term IOP management in the immediate postoperative period until the vicryl suture lyses. After that, 8-0 Vicryl sutures will be used to close the conjunctiva and tenon’s capsule using both interrupted and running procedures.
Primary outcome measures
1) Visual acuity testing by Snellen’s chart:
It is used to assess distant visual acuity. The patient is seated 6m away from the Snellen’s chart and is instructed to read the chart with both eyes, one after the other. When the patient can read up to a 6 m line, his visual acuity is reported as 6/6, and depending on the smallest line that the patient can read from a 6 m distance, his vision is recorded as 6/9, 6/12, 6/18, 6/24, 6/36, and 6/60.
2) Intra Ocular Pressure measurement by applanation tonometry:
The Goldmann Applanation Tonometer is commonly recognized as the gold standard in intraocular pressure (IOP) measurement. A topical anesthetic is instilled into the conjunctival sac, followed by a fluorescein stain. The cobalt blue filter reveals a pattern of two green semicircular mires, with the inner borders of semicircles aligned. The IOP is calculated by multiplying the dial value by ten in mmHg.
Secondary outcome measures
1) Moorfields bleb grading (Figure 1):
The bleb is assessed and characterized with respect to:
2) Need of anti-glaucoma medication:
If the post-operative IOP measurement indicates greater values, we will administer anti-glaucoma drugs later.
3) OCT-RNFL and Humphrey visual field analysis.
Using sample size formula with desired error of margin
Where Zα/2 is the level of significance at 5% i.e.:
99.5% confidence interval = 2.8
P = Prevalence of secondary glaucoma = 0.50% i.e. 0.005
d = Desired error of margin = 5% = 0.05
n = 14.8
n = 15 patient needed in each group.
Total sample size = 30
Study reference: Arun Narayanaswamy et al.13
Formula reference: Daniel et al.14
Sample size: After meeting the inclusion and exclusion requirements, a total of 30 SUBJECTS will be registered in this interventional cross-sectional hospital-based study.
This will be done with the aid of descriptive and inferential statistics, chi-square tests, odds ratios, and software analysis with the SPSS-24.0 system and Graph Pad prism 7.0 version and p < 0.05 is considered as level of significance.
In this study, we compared the clinical outcomes of glaucoma drainage tube implantation to traditional trabeculectomy. The most frequent etiology of vision loss and blindness is glaucoma. In India, it is the second most frequent reason for blindness, and the majority of people are unaware of the cure. There has been very little study in this field to evaluate the efficiency of glaucoma drainage devices and routine trabeculectomy. As a result, we intend to compare the therapeutic effects of glaucoma drainage devices and conventional trabeculectomy in AVBRH patients with uncontrolled primary and refractory glaucoma.
A detailed analysis of GDDs revealed that the Baerveldt and Ahmed implants’ respective IOP changes were roughly 54 and 51%.15 After a year, Harbick et al. discovered a considerable net decline in visual acuity, which they attributed to concurrent pre-existing retinal and corneal problems.16 Patients who underwent tube shunt surgery versus those who underwent trabeculectomy with MMC during the first three years of follow-up were more likely to maintain IOP control and avoid persistent hypotonia, or reoperation for glaucoma.17
According to Joshi et al., glaucoma drainage implants have become an essential surgical option for treating secondary glaucoma. Although these implants were previously utilised solely after a failed trabeculectomy, they are now increasingly being employed as a main surgical technique in cases of uveitic glaucoma.18
In 10 patient’s 14 eyes with uveitic glaucoma associated with Behcet’s disease, Satana et al. reported that AGV implantation led to 90.9% success rates after 18 months and 72.7% success rates after 2 years.19 Retrospective investigation of uveitic glaucoma patients 60 eyes who underwent AGV implantation indicated success rates of 77.0% after one year and 50.0% after four years (IOP range of 5 to 21 mmHg and a 25.0% decrease in IOP from before surgery.20 Preoperative corticosteroid usage may increase AGV surgical outcome in uveitic glaucoma. Preoperative prednisone at 1 mg/kg/day was indicated by Mata et al. until the inflammation was controlled. Oral corticosteroids are decreased during a four-week period following surgery.21
In eyes with chronic inflammatory glaucoma, N. Bhardwaj, S. M. Iverson, W. Shi, and colleagues found that implantation of the Baerveldt Glaucoma Drainage Device was more likely to maintain IOP control and prevent glaucoma reoperation than trabeculectomy with antifibrotic therapy.22
I would like to acknowledge Mr Laxmikant Umate Sir, who has helped me in sample size calculation and data analysis planning.
Views | Downloads | |
---|---|---|
F1000Research | - | - |
PubMed Central
Data from PMC are received and updated monthly.
|
- | - |
Is the rationale for, and objectives of, the study clearly described?
Yes
Is the study design appropriate for the research question?
Partly
Are sufficient details of the methods provided to allow replication by others?
Yes
Are the datasets clearly presented in a useable and accessible format?
Not applicable
Competing Interests: No competing interests were disclosed.
Reviewer Expertise: Glaucoma
Alongside their report, reviewers assign a status to the article:
Invited Reviewers | |
---|---|
1 | |
Version 1 29 Aug 23 |
read |
Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list:
Sign up for content alerts and receive a weekly or monthly email with all newly published articles
Already registered? Sign in
The email address should be the one you originally registered with F1000.
You registered with F1000 via Google, so we cannot reset your password.
To sign in, please click here.
If you still need help with your Google account password, please click here.
You registered with F1000 via Facebook, so we cannot reset your password.
To sign in, please click here.
If you still need help with your Facebook account password, please click here.
If your email address is registered with us, we will email you instructions to reset your password.
If you think you should have received this email but it has not arrived, please check your spam filters and/or contact for further assistance.
Comments on this article Comments (0)